Principle Wealth Partners LLC Acquires Shares of 3,345 Thermo Fisher Scientific Inc. $TMO

Posted by Brian Himes on Aug 19th, 2026

Principle Wealth Partners LLC acquired a new position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report) in the 2nd quarter, HoldingsChannel reports. The institutional investor acquired 3,345 shares of the medical research company’s stock, valued at approximately $1,677,000.

Several other large investors have also recently bought and sold shares of TMO. Legacy Wealth Managment LLC ID lifted its position in shares of Thermo Fisher Scientific by 78.6% during the 1st quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company’s stock worth $25,000 after buying an additional 22 shares during the last quarter. Allied Private Wealth LLC purchased a new position in shares of Thermo Fisher Scientific in the 2nd quarter valued at approximately $26,000. High Note Wealth LLC increased its stake in Thermo Fisher Scientific by 170.6% in the 4th quarter. High Note Wealth LLC now owns 46 shares of the medical research company’s stock valued at $27,000 after buying an additional 29 shares during the period. Swiss RE Ltd. acquired a new position in shares of Thermo Fisher Scientific during the fourth quarter worth about $28,000. Finally, JPL Wealth Management LLC purchased a new position in Thermo Fisher Scientific during the third quarter worth about $28,000. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $574.47, for a total transaction of $5,744,700.00. Following the completion of the transaction, the chief executive officer directly owned 123,925 shares in the company, valued at approximately $71,191,194.75. This trade represents a 7.47% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction dated Monday, July 27th. The stock was sold at an average price of $565.00, for a total transaction of $226,000.00. Following the transaction, the chief operating officer owned 24,651 shares of the company’s stock, valued at approximately $13,927,815. The trade was a 1.60% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 52,053 shares of company stock worth $30,643,589. Insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Price Performance

TMO stock opened at $590.00 on Wednesday. The firm has a 50 day moving average of $533.64 and a 200-day moving average of $508.36. The company has a market cap of $218.15 billion, a price-to-earnings ratio of 31.74, a PEG ratio of 2.39 and a beta of 0.84. The company has a current ratio of 1.55, a quick ratio of 1.18 and a debt-to-equity ratio of 0.74. Thermo Fisher Scientific Inc. has a 12-month low of $435.27 and a 12-month high of $643.99.

Thermo Fisher Scientific (NYSE:TMO – Get Free Report) last released its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share for the quarter, topping analysts’ consensus estimates of $5.71 by $0.32. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The business had revenue of $11.99 billion for the quarter, compared to analysts’ expectations of $11.71 billion. During the same quarter in the prior year, the firm posted $4.28 EPS. The company’s revenue was up 10.5% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. As a group, equities analysts expect that Thermo Fisher Scientific Inc. will post 25.12 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be issued a $0.47 dividend. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $1.88 annualized dividend and a yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio is 10.11%.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on TMO shares. Jefferies Financial Group reaffirmed a “buy” rating and issued a $630.00 price objective on shares of Thermo Fisher Scientific in a report on Thursday, July 23rd. Royal Bank Of Canada raised their price target on Thermo Fisher Scientific from $490.00 to $580.00 and gave the company a “sector perform” rating in a report on Friday, July 24th. Piper Sandler upped their price objective on Thermo Fisher Scientific from $510.00 to $600.00 and gave the stock a “neutral” rating in a report on Monday, July 27th. Wall Street Zen upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research report on Saturday, August 1st. Finally, Weiss Ratings upgraded shares of Thermo Fisher Scientific from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday, July 14th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $619.41.

View Our Latest Research Report on TMO

Thermo Fisher Scientific Profile

(Free Report)

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.